Indivior Plc (INDV) Stock Price, Quote & News

Company Profile

Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sub...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 804 379 1040

Website: www.indivior.com

Address:

10710 Midlothian Turnpike, Suite 125, North Chesterfield, United States

EarningsInsider Aug. 3 at 1:46 PM

https://www.marketbeat.com/earnings/reports/2026-8-3-indivior-plc-stock-1/ $INDV Indivior Earnings Transcript

0 · Reply

DonCorleone77 Aug. 3 at 1:17 PM

$ATKR $FERG $SUPN $INDV $BMY PRE-MARKET MOVERS: Currently Higher: - Atkore (ATKR) up 27.9% after entering into a definitive agreement to be acquired by Prysmian in an all-cash transaction representing an enterprise value of approximately $3.8B - Ferguson (FERG) up 8.2% ahead of its entry into the S&P 500 - Supernus (SUPN) up 14.3% after the company and Indivior entered into a definitive agreement to combine in a tax-free all-stock merger of equals transaction - Indivior (INDV) up 1.2% after Supernus and the company entered into a definitive agreement to combine in a tax-free all-stock merger of equals transaction - Bristol Myers (BMY) up 3.1% after Financial Times reported AstraZeneca (AZN) is in discussions to combine with the company in a deal valued at nearly $400B Currently Lower After Earnings: - Sportradar (SRAD) down 19.2% - Krystal Biotech (KRYS) down 5.6% - TG Therapeutics (TGTX) down 2.7% - Marriott (MAR) down 2.2% Currently Also Lower: - AstraZeneca (AZN) down 7.1% after Financial Times reported the company is in discussions to combine with Bristol Myers Squibb in a deal valued at nearly $400B - Circle Internet (CRCL) down 5.6% after Morgan Stanley downgraded the stock to Underweight with a price target of $38, down from $106

0 · Reply

briefingcom Aug. 3 at 12:30 PM

$SUPN: Supernus Pharma (+14.3%) and Indivior Pharmaceuticals $INDV to merge; expected to close in Q4 of 2026.

0 · Reply

notreload_ai Aug. 3 at 12:00 PM

$SUPN and $INDV merge to form a diversified CNS biopharma powerhouse with $2.2B revenue, $125M annual synergies, and greater growth flexibility. https://notreload.xyz/xy/supn-indv-merge-to-form-2-2b-cns-leader/

0 · Reply

StocktwitsEarnings Aug. 3 at 10:58 AM

$INDV Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $5.10 up 580.00% YoY • Reported revenue of $343M up 13.58% YoY • Indivior raised its full-year 2026 financial guidance, now expecting net revenue of $1,295 million to $1,365 million, total SUBLOCADE net revenue of $1,010 million to $1,050 million, and adjusted EBITDA of $700 million to $740 million.

0 · Reply

JodieChristy Jul. 19 at 8:58 PM

Hugging the line! $INDV tests the 21-EMA as the next move takes shape Indivior ($INDV) finished at $40.54. The stock absorbed recent healthcare sector rotation and continues building a base while holding near its key short-term trend line. This is a classic 21-EMA continuation setup. Bulls need volume confirmation to push price above the current consolidation zone and trigger a possible momentum breakout. If the breakout takes longer, the previous horizontal support area remains the key accumulation zone. The chart is showing patience, not weakness. The next reaction from this level could define the short-term trend. Charts tell the story before headlines do.

0 · Reply

doctorwho Jul. 16 at 1:45 PM

$INDV I made an entry to invest how I can into suboxone From my understanding it will help people get off the gas station heroin which is supposed to be banned soon 🤷‍♂️ I pray for anyone addicted to drugs

1 · Reply

ripster47 Jun. 18 at 11:29 AM

$INDV | Barclays Starts Indivior at Overweight with $46 PT on EBITDA Growth and Sublocade Momentum Barclays stays bullish as management execution, cost optimization, and mid-teens Sublocade growth support long-term upside. 🔹 Follow @tenet_research for more analyst insights on other tickers.

0 · Reply

SuperGreenToday May. 26 at 2:20 PM

$INDV Share Price: $37.65 Contract Selected: Nov 20, 2026 $40 Calls Buy Zone: $2.72 – $3.36 Target Zone: $4.73 – $5.78 Potential Upside: 64% ROI Time to Expiration: 177 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

NVDAMillionaire May. 14 at 1:29 AM

$INDV Outstanding article that hits the mark on INDV's current state. So if you want to refresh your INDV insights or learn about INDV from scratch, this is a must read. https://everyticker.com/quote/INDV/analysis/indivior-s-sublocade-transformation-margin-inflection-meets-patent-protected-growth-nasdaq-indv

0 · Reply